Abstract
In the last 20 years, the cost and turnaround time for whole genome sequencing (WGS) has decreased dramatically, while the number of genetic diseases of known molecular basis has steadily increased, as has the number of investigational new drug applications for gene-targeted therapeutics (GTT). GTTs have the potential to transform outcomes in genetic disorders by directly targeting the causative molecular defect. The United States Congress and Food and Drug Administration (FDA) have implemented policies that are accelerating GTT development through the Orphan Drug Act and recent guidelines for GTTs, real-world evidence, and surrogate endpoints.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.